AA Pharma Bromocriptine Adverse Reactions

The most frequently observed adverse reactions are nausea, vomiting, headache and gastrointestinal side effects such as abdominal pain, diarrhea and constipation. All these effects may be minimized or even prevented by giving small initial doses of bromocriptine and by taking it with food.
Postural hypotension can, on rare occasions, lead to fainting, and shock-like syndromes have been reported in sensitive patients. This is most likely to occur during the first few days of AA PHARMA BROMOCRIPTINE (bromocriptine mesylate) treatment.
In clinical studies to date, the incidences of adverse reactions were noted for the following indications: Amenorrhea/Galactorrhea/Female Infertility/Acromegaly: The incidence of side effects in these indications is higher (68%), reflecting the larger doses required, but they are generally mild to moderate in degree. Therapy was discontinued in approximately 6% of patients because of adverse effects. In decreasing order of frequency these are: nausea 49%, headache 19%, dizziness 17%, fatigue 7%, abdominal cramps 4%, lightheadedness 5%, vomiting 5%, nasal congestion 3%, constipation 3%, diarrhea 3% and drowsiness 3%.
Parkinson's Disease: When bromocriptine is added to levodopa therapy, the incidence of adverse reactions may increase. The most common newly appearing adverse reactions in combination therapy were: nausea, abnormal involuntary movements, hallucinations, confusion, "on-off" phenomenon, dizziness, drowsiness, faintness, fainting, vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, depression, hypotension, shortness of breath, constipation and vertigo.
General: Less common adverse reactions include: anorexia, anxiety, blepharospasm, epileptiform seizures, fatigue, headache, lethargia, mottling of skin, nasal stuffiness, nervousness, nightmares, paresthesia, skin rash, urinary frequency, urinary incontinence, urinary retention and rarely signs and symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud's syndrome.
Abnormalities in laboratory tests may include elevation of blood urea nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient and not of clinical significance.
The occurrence of adverse reactions may be lessened by temporarily reducing the dosage to one half-tablet two or three times daily.